Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 15, 2023
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
Corinne Jenkins Maintained (BTAI) at Hold with Decreased Target to $4 on, Aug 15th, 2023
Corinne Jenkins of Goldman Sachs, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Hold with Decreased Target from $12 to $4 on, Aug 15th, 2023.
Corinne has made no other calls on BTAI in the last 4 months.
There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 1 agrees with Corinne's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023
This is the rating of the analyst that currently disagrees with Corinne
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $60 on, Monday, July 3rd, 2023
